MedTrace Logo

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

NCT03095807 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-10-05

No results posted yet for this study

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with obesity.

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Interventions

DRUG

NNC9204-1706 A

Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.

DRUG

Placebo

Administered subcutaneously (s.c., under the skin)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-20
Primary Completion
2017-08-31
Completion
2017-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03095807 on ClinicalTrials.gov